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ABSTRACT
Background: Replacing dietary saturated fatty acids (SFAs) with
polyunsaturated fatty acids (PUFA) reduces the plasma low-density
lipoprotein (LDL) cholesterol and subsequently the risk of cardiovas-
cular disease. However, beyond changes in LDL cholesterol, we lack
a complete understanding of the physiologic alterations that occur
when improving dietary fat quality.
Objectives: The aim of this study was to gain knowledge of
metabolic alterations paralleling improvements in the fat quality of
the diet.
Methods: We recently conducted an 8-wk, double-blind, ran-
domized controlled trial replacing SFAs with PUFAs in healthy
subjects with moderate hypercholesterolemia (n = 99). In the present
substudy, we performed comprehensive metabolic profiling with
multiple platforms (both nuclear magnetic resonance- and mass
spectrometry-based technology) (n = 99), and analyzed peripheral
blood mononuclear cell gene expression (n = 95) by quantitative
real-time polymerase chain reaction.
Results: A large number of lipoprotein subclasses, myristoylcar-
nitine and palmitoylcarnitine, and kynurenine were reduced when
SFAs were replaced with PUFAs. In contrast, bile acids, proprotein
convertase subtilisin/kexin type 9, acetate, and acetoacetate were
increased by the intervention. Some amino acids were also altered
by the intervention. The mRNA levels of LXRA and LDLR were
increased, in addition to several liver X receptor α target genes and
genes involved in inflammation, whereas the mRNA levels of UCP2
and PPARD were decreased in peripheral blood mononuclear cells
after replacing SFAs with PUFAs. Partial least squares-discriminant
analysis showed that the 30 most important variables that contributed
to class separation spanned all classes of biomarkers, and was in
accordance with the univariate analysis.
Conclusions: Applying metabolomics in randomized controlled
dietary intervention trials has the potential to extend our knowledge
of the biological and molecular effects of dietary fat quality. This
study was registered at clinicaltrials.gov as NCT 01679496. Am
J Clin Nutr 2019;109:1239–1250.
Keywords: cardiovascular risk factors, fatty acids, lipoprotein
subclasses, metabolic profiling, acylcarnitines, tryptophan, nutrition,
gene expression
Introduction
Cardiovascular disease (CVD) remains the major contributor
to the global burden of disease (1). CVD is associated with
conditions of perturbed energy homeostasis and metabolism.
Replacing saturated fatty acids (SFAs) with polyunsaturated
fatty acids (PUFAs) has been linked to a reduced risk of CVD
(2, 3). In addition, controlled metabolic studies have shown
the importance of fat quality on LDL cholesterol (4, 5), and
dietary randomized controlled trials (RCTs) have shown that
replacing SFAs with PUFAs significantly reduces plasma LDL
cholesterol (6–10). It is generally recognized that beyond the
well-established associations between CVD and traditional risk
factors, such as LDL cholesterol, comprehensive knowledge of
metabolic dysregulation in subjects at risk of CVD, or patients
with CVD, is still lacking. We recently performed a double-blind,
randomized controlled dietary intervention study exchanging
similar food items with improved fat quality (replacing SFAs with
PUFAs), which led to an 11% reduction in LDL cholesterol and
a 9% reduction in total cholesterol in the experimental (Ex-diet)
group compared with the control-diet (C-diet) group (10).
Comprehensive metabolic profiling or “metabolomics” has
emerged as an important tool to identify novel biomarkers of
CVD development (11). Metabolomic techniques assess a large
number of metabolites. Variations in the concentrations of these
metabolites result from genomic, transcriptomic, and proteomic
variability; thus, they provide an integrated and dynamic
measure of phenotype. Cohort studies that use metabolomics
have identified a large number of metabolites linked to CVD
risk (12–15), but more research is needed to identify novel
biomarkers in prevention and treatment of CVD. Interestingly,
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the human metabolome indeed responds to changes in dietary
patterns (16–20), but the specific effects of replacing SFAs
with PUFAs in the diet on the metabolome remain largely
unknown. Integrating metabolomics with dietary RCTs may help
us understand the molecular pathophysiologic processes of CVD,
define metabolic changes from diet, identify their associations
with disease risk, and discover novel biomarkers and targets for
intervention.
To further understand the metabolic alterations paralleling
improved fat quality of the diet, we performed targeted metabolic
profiling of biomarkers shown to be associated with CVD risk.
Finally, we analyzed the gene expression level of genes involved
in lipid metabolism and inflammation.
Methods
Study design and subjects
We conducted an 8-wk, double-blind, randomized controlled
dietary intervention study at the Oslo and Akershus University
College of Applied Sciences and the University of Oslo, Norway,
from July 2012 until April 2014. The study design and description
of participants has been reported in detail previously (10).
In short, 701 subjects were assessed for eligibility, 115 were
randomly assigned, 100 completed the study, and 99 were
analyzed independent of the compliance (Supplemental Figure
1). The participants were healthy adults aged 25–70 y with LDL
cholesterol ≥3.5 mmol/L, total cholesterol was within the normal
range for each age group, and triglycerides (TGs) were ≤2.6
mmol/L. The participants had stable body weight during the 3
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mo (±5%) preceding the start of the study, and a BMI between 20
and 35 kg/m2. In the present analyses, 99 subjects (58% women)
were included.
Before the baseline visit, all subjects performed a 2-wk run-
in period in which they included the control food items in their
daily diet. At baseline, subjects were randomly assigned to 1 of 2
intervention groups (1:1 ratio), stratified by gender and age. The
C-diet group continued with the control food items, and the Ex-
diet group received experimental food items. The experimental
food items were the same type of products as the control, but with
a different fat composition [SFAs replaced with mostly n–6 (ω-6)
PUFAs]. The food items in the C-diet group or the Ex-diet group
were respectively butter-based spread or margarine-based spread,
butter or liquid margarine, and olive oil or rapeseed and sunflower
oil. In addition, products such as liver paté, cheese, bread, muesli
cereals, cream, mayonnaise, and crème fraîche were given to the
participants, and some of the SFAs were replaced with rapeseed
and sunflower oils in the products in the Ex-diet group. Based on
the minimum intake of the food items, the n–6 PUFA content was
4.2 g/d in the control food items and 12.9 g/d in the experimental
food items, and the SFA content was 19.2 and 5.7 g/d in the
control food items and the experimental food items, respectively.
Among the SFAs, the content of palmitic acid was 9.2 g/d in the
control food items and 2.7 g/d in the experimental food items,
whereas the content of myristic acid was 2.9 and 0.2 g/d in the
control food items and experimental food items, respectively.
The content of monounsaturated fatty acids in the food items
was the same in both groups. Details about the study products
are described elsewhere (10). The dietary difference during the
intervention was 6.5 energy % (E%) lower intake of SFAs and
6.4 E% higher intake of PUFAs in the Ex-diet group compared
with the C-diet group. In addition, the protein intake was 1.5
E% higher, and the fiber intake was 11.5 g/day higher, whereas
the carbohydrate intake was 2.4 E% lower in the Ex-diet group
than in the C-diet group during the intervention (10). Clinical
and blood laboratory assessments were performed at baseline and
after 8 wk follow-up.
The study was conducted according to the guidelines laid
down in the Declaration of Helsinki. All subjects gave written
informed consent, and the Regional Ethics Committee for
Medical Research in South East Norway approved the study. The
study was registered at clinicaltrials.gov as NCT 01679496.
Blood sampling and standard laboratory analysis
The day before blood sampling, the subjects were told to
refrain from alcohol consumption and vigorous physical activity.
Venous blood samples were drawn after an overnight fast (≥12 h).
Serum was obtained from silica gel tubes (Becton Dickinson
Vacutainer Systems) and kept at room temperature for ≤30 min,
until centrifugation (1500 × g, 15 min). Plasma was obtained
from EDTA tubes (Becton Dickinson Vacutainer), immediately
placed on ice, and centrifuged within 10 min (2000 × g, 4◦C,
15 min). EDTA tubes with whole blood were kept at room
temperature for ≤48 h before counting the total number of
lymphocytes and monocytes (Fürst Medical Laboratory). Fasting
serum concentrations of high-sensitivity C-reactive protein (hs-
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lipoprotein A, TGs, and glucose were measured by standard
methods at a routine laboratory (Fürst Medical Laboratory) as
previously described (10).
Biochemical analysis and targeted metabolic profiling
The concentration of proprotein convertase subtilisin/kexin
type 9 (PCSK9) was measured in serum by enzyme immunoas-
says from R&D Systems. Serum bile acid level was measured
by colorimetric photometry at the Department for Medical
Biochemistry, Oslo University Hospital, Rikshospitalet, Norway.
All samples were batch analyzed at the end of the study.
Mass spectrometry-based analyses and microbiological assays.
We measured plasma metabolites and related biomarkers at
Bevital (www.bevital.no) with the use of several targeted assays
(platforms A–H) to quantify concentrations of amino acids
and amino acid metabolites, gut flora metabolites, cystatin C
variants, B vitamins, folates, fat-soluble vitamins, inflammation
markers, and miscellaneous other metabolites (21–27). More
specifically, total homocysteine, methylmalonic acid, total
cysteine, methionine, serine, glycine, and cystathionine were
measured at platform A by gas chromatography tandem mass
spectrometry (GC-MS/MS). Histidine, tryptophan, kynurenine,
ornithine, aspartic acid, glutamic acid, lysine, alanine, isoleucine,
leucine, proline, valine, asparagine, glutamine, threonine,
tyrosine, phenylalanine, and α-ketoglutaric acid/oxoglutaric acid
were measured at platform B by GC-MS/MS. Choline, betaine,
dimethylglycine, creatine, methionine sulfoxide, arginine
asymmetric dimethylarginine, symmetric dimethylarginine,
homoarginine, trimethyllysine, trimethylamineoxid, creatinine,
1-methylhistidine, and 3-methylhistidine were measured at
platform C by liquid chromatography (LC)-MS/MS (LC-
MS/MS). Pyridoxal 5′-phosphate, pyridoxal, 4-pyridoxic
acid, thiamine, thiamine monophosphate, riboflavin, flavin
mononucleotide, neopterin, 3-OH-kynurenine, kynurenic
acid, xanthurenic acid, anthranilic acid, 3-OH-anthranilic
acid, picolinic acid, quinolinic acid, nicotinamide, N1-
methylnicotinamide, and trigonelline were measured at
platform D by LC-MS/MS. 5-Methyl-tetrahydrofolate, 4-a-
OH-5-methyl-tetrahydrofolate, para-aminobenzoylglutamate,
and acetamidobenzoylglutamate were measured at platform E by
LC-MS/MS. All-trans retinol, 25-OH-vitamin D3, α-tocopherol,
γ -tocopherol, and phylloquinone were measured on platform
H by LC-MS/MS. Cystatin C and variants were measured
at platform G by matrix-assisted laser desorption/ionization
time-of-flight MS, and cobalamine was measured at platform F
through the use of microbiological assay.
Additionally, free carnitine, short-, medium-, and long-chain
acylcarnitines, and the precursors for carnitine, trimethyllysine,
and butyrobetaine, were analyzed in plasma by LC-MS/MS (28).
All samples were batch analyzed at the end of the study.
Nuclear magnetic resonance spectroscopy-based analyses.
Metabolic biomarkers were quantified from EDTA plasma
with the use of a commercial high-throughput nuclear mag-
netic resonance (NMR) spectroscopy platform (Nightingale,
https://nightingalehealth.com). This method quantifies 14 sub-
classes of lipoprotein particles, particle sizes, and apolipopro-
teins, as well as various fractions of cholesterol, TGs, phos-
pholipids, albumin, 3-hydroxybutyrate, acetate, acetoacetate,
lactate and citrate, and glycoprotein acetyls. Details of the
performance of the NMR metabolomics platform have been
described previously (29). All samples were batch analyzed at
the end of the study.
Peripheral blood mononuclear cell isolation
After blood collection, peripheral blood mononuclear cells
(PBMCs) were isolated with the use of BD Becton Dickinson Va-
cutainer Cell Preparation tubes according to the manufacturer’s
instructions and stored as pellets at −80◦C until further analysis.
This is a well-documented and standardized method to collect
mononuclear cells with high purity (>90%), and, according to
the manufacturer, ∼80% of the cells are lymphocytes and 12%
are monocytes.
RNA isolation, cDNA synthesis and quantitative real-time
polymerase chain reaction
Total RNA was isolated with the use of an RNeasy Mini
Kit according to the manufacturer’s instructions (Qiagen), RNA
quantity measurements were performed with a Nanodrop ND-
1000 spectrophotometer (Thermo Fisher Scientific), and the RNA
integrity number (RIN) value was measured with an Agilent
2100 Bioanalyzer (Agilent Technologies) to check the RNA
quality. Only samples with RIN values of 8–10 were used for
the gene expression analysis. RNA from all samples was reverse
transcribed by a high-capacity cDNA reverse transcription kit
(Applied Biosystems). For quantitative real-time polymerase
chain reaction, we used TaqMan Array Micro Fluidic Cards
(Applied Biosystems) on an ABI PRISM 7900HT (Applied
Biosystems). TATA box binding protein (TBP) and glucuronidase
β (GUSB) were used as endogenous controls for normalization
of cDNA amount in ExpressionSuite version 1.0.2 (= Ct). The
relative mRNA level for each transcript was calculated by the 
cycle threshold method (30).
Statistical analysis
This study was designed based on the primary outcome of
the study, which was LDL cholesterol concentration (10). Power
calculations estimated that 180 subjects (including a 20% drop-
out rate) were required to obtain 80% power with a type I
error of 5% to detect a difference between the 2 groups of
8% in LDL cholesterol concentration at the end of the study.
Post-hoc analyses showed that the number of subjects recruited
gave sufficient power with the observed 10% change in LDL
cholesterol between the groups (n = 47 subjects in each group).
Prespecified secondary outcomes were other lipids, inflammatory
markers, metabolomics, and transcriptomics.
Statistical analyses were performed in R version 3.5.0
with RStudio IDE (31) (www.rstudio.com). In the following
description, R package name, function name, and relevant setting
are stated in parentheses, e.g. (package::function, setting = 123).
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TABLE 1 Baseline characteristics and changes in clinical and standard biochemical measurements after the 8-wk intervention1
C-diet group (n = 52) Ex-diet group (n = 47)
Baseline Change Baseline Change P
Clinical measurements
Age, y 55.2 ± 9.8 — 53.6 ± 9.7 —
Gender: female, n (%) 31 (59.6) — 27 (57.4) —
Smokers, n (%) 9 (17.3) — 4 (8.5) —
Weight, kg 74.1 ± 13.1 0.4 ± 1.1 75.7 ± 12.7 0 ± 1.1 0.044
BMI, kg/m2 24.6 ± 3 0.1 ± 0.3 25.4 ± 2.9 0 ± 0.4 0.043
Biochemical measurements
Total cholesterol, mmol/L 6.6 ± 0.8 0 ± 0.5 6.6 ± 0.8 −0.5 ± 0.6 <0.001
LDL cholesterol, mmol/L 4.1 ± 0.6 0 ± 0.5 4.2 ± 0.6 −0.4 ± 0.5 <0001
HDL cholesterol, mmol/L 1.7 ± 0.4 0 ± 0.2 1.7 ± 0.5 −0.1 ± 0.1 0.005
TG, mmol/L 1.2 (0.5) 0.1 (0.3) 1.3 (0.7) 0 (0.5) 0.002
Lipoprotein (a), mg/dL 180.5 (365.2) 0 (21) 115.5 (461) 0.5 (20.8) 0.95
Glucose, mmol/L 5.2 (0.5) −0.1 (0.4) 5.3 (0.5) 0 (0.4) 0.37
hs-CRP, mg/L 1.0 (1.4) 0.1 (1.6) 1.2 (1.6) −0.1 (0.9) 0.24
1Data are shown as mean ± SD or median (IQR). P, between-group changes: independent t test or Mann-Whitney U test. C-diet group, control diet
group; Ex-diet group, experimental diet group; hs-CRP: high-sensitivity C-reactive protein; TG, triglyceride.
and 25th–75th percentile (IQR) for continuous variables, or as
counts and percentage for categoric variables. For a full overview
of numeric data for all outcome variables, see Supplemental
Table 1.
Univariate analyses.
For standard clinical and biochemical measurements in Table
1, independent-samples t tests were used to assess changes
between groups when the data were normally distributed, and the
MannWhitney U test was used to assess changes between groups
when the data were not normally distributed for continuous
variables. We then constructed linear regression models fitted
for each of the 173 outcome variables, based on the use of
group affiliation (dichotomous variable) as the main exposure
(stats::lm). In the analyses presented in Figures 1–3, we adjusted
for age, gender, intervention-related weight change, and baseline
value. In sensitivity analyses, we examined both crude estimates
and estimates not adjusted for baseline value (Supplemental Table
1). We normalized (centered to mean = 0, and scaled SD = 1)
all measures to aid comparison of magnitudes and to improve
visualization of the results (base::scale). The gene expression data
was log2 transformed before normalization. In Supplemental
Figures 2–4 we show analyses from baseline to the end of the
study (within groups).
The nominal significance (α) level was set to 0.05. However,
to adjust for the large number of tests, we calculated the false
discovery rate (FDR) (stats::p.adjust, method = “fdr”), which
offers a BenjaminiHochberg adjustment of a list of P values.
This method corresponds to a tail area–based FDR (or q value),
and can be interpreted in the usual frequentist way, just like the
regular P value. We set the FDR significance level to 0.2 due to
the explorative nature of the study.
Multivariate analyses.
In multivariate analyses, hierarchic clustering and partial
least squares-discriminant analysis (PLS-DA) were performed.
Input data for these analyses were changes in all 173 variables
reported in the manuscript (from baseline to the end of the
study, for both study groups). Clustering was used to find
similarities and dissimilarities between groups of variables in
an unsupervised manner. We calculated the Spearman corre-
lation matrix (stats::cor, use = “pairwise.complete.obs”), and
the Euclidean distance of this correlation matrix (stats::dist,
method = “euclidean”), and performed hierarchic clustering of
this distance object (stats::hclust, method = “complete”). After
visualizing and cutting the tree with different values of both
height (h) and numbers of clusters (k), we decided to cut the tree
into 10 clusters (stats::cutree, k = 10).
PLS-DA was used for supervised dimension reduction and
classification, and to compare the results from univariate analyses
and clustering. The data were split into training and test sets.
To prevent class imbalances in doing this, we stratified on
study group (caret::createDataPartition). In order to maintain a
relatively large and reliable test set, the data were split into
training and testing in a 60:40 ratio. All model training and
validation was performed on the training set, whereas the test set
was only used once (with the same settings for preprocessing,
such as imputation, centering, and scaling). PLS-DA analysis
was performed with the use of the default orthogonal scores
algorithm (nonlinear iterative partial least squares, NIPALS). For
these analyses, we used the train function and associated helper
functions (trainControl, twoClassSummary, and preProc) imple-
mented in the caret package in R (caret::train, method = “pls”).
We evaluated between 1 and 15 PLS components with the use
of repeated 10-fold cross-validation (3 repeats). To evaluate
the performance of each model, we used the area under the
receiver operating characteristic (ROC) curve. We preprocessed
the training data by median imputation, centering, and scaling.
A final PLS-DA model was fitted to the whole training set based
on the use of 3 components (area under the ROC curve = 0.92),
and this model was further used to predict samples in the
test set (stats::predict). To obtain the class probabilities, the
default softmax algorithm was used. In addition, we acquired the








niversitetsbiblioteket i Bergen user on 16 April 2020
Metabolic profiling, gene expression and dietary fat quality 1243










































P value < 0.001 < 0.01 < 0.05 ≥ 0.05







FIGURE 1 Lipid particles, lipid species, bile acids, and other miscel-
laneous proteins: between-group differences in change from baseline to the
end of the study. Concentration of lipoprotein particles, apolipoproteins,
cholesterol, triglycerides, phospholipids, and miscellaneous factors in the
Ex-diet group (symbols, n = 47) compared with the C-diet group (black
dashed line, n = 52). Estimates on the right and left side of the zero
line indicate an increase and decrease, respectively, in the Ex-diet group,
compared with the C-diet group. Colors denote P value significance level,
and shapes denote FDR q values, as indicated in the figure legend. The
data are normalized (centered to mean = 0; scaled to SD = 1), adjusted
for age, gender, intervention-related weight change, and baseline value, and
presented as linear regression β coefficients. Error bars are 95% CIs for
the estimates. Numeric data corresponding to this figure can be found in
Supplemental Table 1; this includes the units of the variables and the number
of nonmissing values per variable. Apo, apolipoprotein; C, cholesterol; Chol,
choline; FDR, false discovery rate; Gp-acetyl, glycoprotein acetyl (mainly
a1-acid glycoprotein); IDL, intermediate-density lipoprotein; L, large; M,
medium; PC, phosphatidylcholine and other cholines; PCSK9, proprotein
convertase subtilisin/kexin type 9; PG, phosphoglyceride; S, small; SM,
sphingomyelin; TG, triglyceride; XL, very large; XS, very small; XXL,
extremely large.
ROC curves of the final prediction model
(plotROC::geom_roc) and of the acquired variable importance
(caret::varImp) were generated, the latter of which is related to
the contribution of variable coefficients to reducing the sum of
squares across PLS components. Finally, biplots comparing PLS
dimensions 1 and 2, and 1 and 3 were created.
Results
For the metabolite analyses, we included data from all 99
participants (47 in the Ex-diet group and 52 in the C-diet group)
who were analyzed in the previously reported RCT (10). For
the gene expression analysis, samples from 95 participants were
available (45 in the Ex-diet group and 50 in the C-diet group)
because the RIN value was <8 in 2 samples, and 2 samples
were lost due to technical error (Supplemental Figure 1). Baseline
characteristics of the 99 participants and the changes during the
intervention of lipids and weight are shown in Table 1.
Quantitative metabolic profiling
Using multiple metabolomics platforms, we measured in total
129 unique features (Figures 1 and 2). The figures display
the normalized differences in change from baseline to end
of study between the Ex-diet group and the C-diet group (β
coefficients ± 95% CI). Estimates on the right or left side of the
zero-line indicate an increase or decrease in the Ex-diet group,
respectively, compared with the C-diet group. The absolute
concentrations before and after intervention in both groups are
shown in Supplemental Table 1.
The fasting concentrations of atherogenic lipoprotein particles,
including LDL, intermediate-density lipoprotein (IDL), and all
the VLDL particles were reduced in the Ex-diet group compared
with the C-diet group following intervention (P < 0.001 for
large [L]-, medium [M]-, and small [S]-LDL, IDL, and very-
small [XS]-VLDL; P < 0.01 for other VLDL particles; q < 0.1
for all) (Figure 1). All HDL particles were reduced in the Ex-
diet group, but only very-large (XL)-HDL particles were reduced
significantly (P < 0.05; q < 0.1).
As expected, the serum total cholesterol, esterified cholesterol,
free cholesterol, and remnant cholesterol were all reduced in the
Ex-diet group compared with the C-diet group after intervention
(P < 0.001 and q < 0.1 for all). Similarly, serum total cholesterol
in VLDL, LDL, and HDL3 were reduced (P < 0.001 and q < 0.1
for all). In addition, the serum total TGs, and serum total TGs
in VLDL, LDL, and HDL were reduced in the Ex-diet group
compared with the C-diet group (P < 0.001 for LDL-TG and
HDL-TG; P < 0.01 for total TG; P < 0.05 for VLDL-TG; q
< 0.1 for all). Phospholipids, such as total phosphoglycerides
(PGs), total cholines, phosphatidylcholines, and sphingomyelins,
were also reduced (P < 0.001 and q < 0.1 for all). The
concentration of glycoprotein acetyls, which reflects the amount
of N-acetyl groups in circulating glycoproteins involved in acute-
phase inflammatory responses, was reduced in the Ex-diet group
during the intervention, whereas the concentration of PCSK9 and
bile acids increased (P < 0.05 for all; q < 0.1 for glycoprotein
acetyls and bile acids; q < 0.15 for PCSK9).
The fasting concentrations of palmitoylcarnitine and myris-
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P value < 0.001 < 0.01 < 0.05 ≥ 0.05
FDR < 0.1 < 0.15 < 0.20 ≥ 0.20
FIGURE 2 Metabolites and biomarkers: between-group differences in change from baseline to the end of the study. Concentration of acylcarnitines,
carnitine, and choline-related metabolites, cystatin C biomarkers, fat-soluble vitamins, folate and B-12–related metabolites, vitamin B–related metabolites,
amino acids, kynurenine and neopterin-related metabolites, and energy metabolites. Overall, the interpretation is as in Figure 1. Numeric data corresponding
to this figure can be found in Supplemental Table 1; this includes the units of the variables and the number of nonmissing values per variable. a,
alpha; ADMA, asymmetric dimethylarginine; b, benzoyl; Carn, carnitine; Cys, cystatin; desS/desSSP/3Pro/CnCt, various cystatin C isoforms; FMN, flavin
mononucleotide; g, gamma; Glu, glutamate; Kyn, kynurenine; m, methyl; mNAM, N1-methylnicotinamide; NAM, nicotinamide; p, phosphate; SDMA,
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FIGURE 3 Gene expression: between-group differences in change from
baseline to the end of the study. Fold change in genes involved in cholesterol
and fatty acid metabolism and inflammation, and percentage level of immune
cells in blood. Overall the interpretation is as in Figure 1. Numeric data
corresponding to this figure can be found in Supplemental Table 1; this
includes the units of the variables and the number of nonmissing values
per variable. ABCA1, ATP-binding cassette transporter A1; ABCG1, ATP-
binding cassette transporter G1; CCR2, C-C chemokine receptor type
2; CD28, cluster of differentiation 28; CD36, cluster of differentiation
36; CD40, cluster of differentiation 40; CD40LG, CD40 ligand; CD8A,
cluster of differentiation 8A; CXCR2, C-X-C motif chemokine receptor
2; FASN, fatty acid synthase; FOXP3, forkhead box P3; GATA3, GATA
binding protein 3; HMGCR, HMG-CoA reductase (3-hydroxy-3-methyl-
glutaryl-coenzyme A reductase); ICOS, inducible T-cell costimulator; IDOL,
increased degradation of LDL receptor protein; IFNG, interferon γ ; IKBKG,
inhibitor of nuclear factor κB kinase subunit γ ; IL1B, interleukin 1β; IL1RN,
interleukin 1 receptor antagonist; IL2RG, interleukin-2 receptor subunit
gamma; IRAK1, interleukin-1 receptor–associated kinase 1; IRF4, interferon
regulatory factor 4; LDLR, low-density lipoprotein receptor; NPC1L1,
Niemann-Pick C1-Like 1; NR1H3, nuclear receptor subfamily 1 group H
member 3; PPARA, peroxisome proliferator–activated receptor α; PPARD,
peroxisome proliferator–activated receptor δ; RELA, nuclear factor κB p65
subunit; SREBF1, sterol regulatory element–binding protein 1; SREBF2,
sterol regulatory element–binding protein 2; TBX21, T-box transcription
factor; TLR4, toll-like receptor 4; TNF, tumor necrosis factor; TNFSF10,
tumor necrosis factor (ligand) superfamily, member 10; TNFSF14, tumor
necrosis factor (ligand) superfamily, member 14; TNFRSF1A, tumor necrosis
factor receptor superfamily member 1A; TNFRSF25, tumor necrosis factor
receptor superfamily member 25; TRAF1, TNF receptor–associated factor 1;
UCP2, mitochondrial uncoupling protein 2.
the C-diet group after intervention (P < 0.001 and q < 0.1
for both) (Figure 2). Interestingly, no other acylcarnitines, total
carnitine, or carnitine metabolites, including betaine, choline, and
the gut flora metabolite trimethylamine N-oxide (TMAO), were
altered after the intervention (Figure 2). No differences between
groups were also observed for cystatin C and other cystatin C–
related biomarkers, fat-soluble vitamins, folate, and vitamin B-12
metabolites (Figure 2). Among other vitamin B and vitamin B–
related metabolites (32), thiamine was increased in the Ex-diet
group compared with the C-diet group (P < 0.05 and q < 0.15)
(Figure 2). Among the amino acids, serine, asparagine, proline,
and the amino acid metabolite cystathionine were increased in
the Ex-diet group compared with the C-diet group at the end
of intervention (P < 0.05 for all; q < 0.1 for asparagine and
cystathionine; q < 0.15 for serine and proline), whereas cysteine
and kynurenine were reduced (P < 0.05 for both; q < 0.15
for cysteine; q < 0.1 for kynurenine) (Figure 2). Acetate and
acetoacetate were increased in the Ex-diet group compared with
the C-diet group after intervention (P < 0.05 for acetate and
P < 0.01 for acetoacetate; q < 0.1 for both) (Figure 2).
PBMC gene expression
We measured gene expression in PBMCs, focusing on genes
involved in lipid metabolism and inflammation, and a total of 44
mRNA transcripts were analyzed (Figure 3; interpretation as for
Figures 1 and 2). The relative mRNA levels after normalizing for
housekeeping genes before and after intervention in both groups
are shown in Supplemental Table 1.
The mRNA levels of nuclear receptor subfamily 1 group H
member 3 [NR1H3, also called LXRA (liver X receptor α)],
LDL receptor (LDLR), ATP-binding cassette transporter G1
(ABCG), sterol regulatory element binding transcription factor
1 (SREBF1), and fatty acid synthase (FASN) were upregulated
in the Ex-diet group compared with the C-diet group (P < 0.05
for NR1H3 and LDLR; P < 0.001 for ABCG1; P < 0.01 for
FASN and SREBF1; q < 0.1 for all), whereas the mRNA levels
of uncoupling protein 2 (UCP2) and peroxisome proliferator-
activated receptor δ (PPARD) were downregulated (P < 0.01 for
UCP2; P < 0.05 for PPARD; q < 0.1 for both) (Figure 3). The
mRNA levels of the inflammatory genes IL-1 receptor–associated
kinase 1 (IRAK1), tumor necrosis factor (ligand) superfamily,
member 14 (TNFSF14), toll-like receptor 4 (TLR4), GATA
binding protein 3 (GATA3), IL-2 receptor subunit γ (IL2RG),
and cluster of differentiation 8A (CD8A) were upregulated in the
Ex-diet group compared with the C-diet group (P < 0.05 for all;
q < 0.1 for IRAK1, TNFSF14, TRL4, and IL2RG; q < 0.15 for
GATA3 and CD8A) (Figure 3).
Multivariate analyses
To strengthen the univariate results, we also performed multi-
variate analyses. First, we used clustering to find similarities and
dissimilarities between groups of variables in an unsupervised
manner. Among the 10 clusters, we found 1 cluster of 3 variables
and 1 of 4 variables, whereas the 8 remaining clusters comprised
between 14 and 25 variables (Figure 4).
Next, we used PLS-DA for supervised dimension reduction
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FIGURE 4 Cluster dendrogram. Clustering of all 173 variables displayed in Figures 1–3. We calculated Spearman’s correlation and Euclidean distance,
and performed hierarchic clustering (complete linkage). The resulting cluster dendrogram was cut into 10 clusters, and both tree branches and labels were
colored according to cluster affiliation. Abbreviations as in Figures 1–3.
had an area under the ROC curve of 0.92 (data not shown),
which indicates good predictive ability. This is supported by
the PLS-DA biplots, showing clear separation of the study
groups (Supplemental Figure 5A, B). Interestingly, the 30
most important variables that contributed to class separation
spanned all classes of biomarkers: lipids (sphingomyelin,
HDL3-C, apolioprotein B, HDL-TG, remnant cholesterol, XS-
VLDL, VLDL cholesterol, S-LDL, free cholesterol, M-LDL, S-
VLDL), metabolites (cystathionine, palmitoylcarnitine, glycine,
kynurenine, acetoacetate, bile acids, α-tocopherol, aspartic acid,
asparagine), and gene expression (NR1H3, IRAK1, CXCR2,
ABCG1, IL18, TNFSF14, IRF4, TNFRSF25, TBX21, FASN)
(Figure 5), which supports and strengthens the results from the
univariate analyses.
Discussion
In this randomized controlled dietary intervention study
among individuals with moderate hypercholesterolemia, lipopro-
tein concentrations of the atherogenic particles were reduced after
replacing SFAs with PUFAs. In addition, PCSK9, bile acids,
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FIGURE 5 Variable importance. Estimated variable importance of the
top 30 highest-ranked variables, determined from a partial least-squares
discriminant analysis (PLS-DA) model. These variables are the most likely
to contribute to the discriminatory ability of the PLS-DA model. All
173 variables have variable importance between 0 and 100. For elaborate
description of the model, see Methods. Abbreviations as in Figures 1–3.
associated with CVD risk, were favorably altered in the Ex-
diet group compared with the C-diet group. In PBMCs, the
mRNA level of several genes involved in lipogenesis, cholesterol
metabolism, β-oxidation, and inflammation were changed during
the intervention (Figure 6).
The lipoprotein particle concentrations of the most atherogenic
particles were reduced in the Ex-diet group compared with
the C-diet group (12). Few other dietary intervention studies
have performed similar comprehensive profiling of candidate
metabolites known to be associated with CVD risk. Measured by
quantitative NMR metabolomics in the FINRISK cohort study,
all VLDL, IDL, and LDL subclasses were associated with higher
risk of future cardiovascular events, whereas the L- and M-HDL
subclasses were associated with lower risk (12). Although the
concentrations of all HDL subclasses were reduced, only the XL-
HDL particle concentration was significantly reduced during the
present intervention study. Thus, replacing SFAs with PUFAs has
a net cardioprotective effect in terms of plasma lipoprotein levels.
The finding that palmitoylcarnitine and myristoylcarnitine
were reduced in the Ex-diet group compared with the C-diet
group supports a beneficial dietary effect of replacing SFAs with
PUFAs. Acylcarnitines are important intermediary components
of energy and fatty acid metabolism, and recent epidemiologic
studies suggest they may be biomarkers of CVD risk in obese and
diabetes patients (33). Even-chained acylcarnitines are associated
with increased risk of diabetes and mortality in patients with
established coronary heart disease (13, 34). Acylcarnitines are
also associated with major cardiovascular events among the
elderly (35), as well as mortality and myocardial infarction (36).
We observed an increase in fasting plasma concentrations of
acetoacetate and acetate in the Ex-diet group, which are metabo-
lites involved in ketogenesis and intermediary metabolism. We
recently showed that children with familial hypercholesterolemia
with higher plasma concentrations of total and LDL cholesterol
had significantly lower plasma concentrations of acetoacetate and
acetate (37). This may be due to reduced uptake of LDL in the
liver (as in familial hypercholesterolemia), creating a temporary
cellular cholesterol deficiency in the hepatocytes, potentially
leading to the utilization of acetate and other carbon sources
for cholesterol synthesis rather than production of acetoacetate.
Another possible explanation of the increased plasma levels of
acetate is that this short-chain fatty acid is produced by gut
microbial fermentation, since fiber intake increased in the Ex-diet
group (38, 39). In addition, the gut microbiota may change due to
changes in fat intake because different fatty acids in serum have
been shown to be associated with different microbiota taxa (40).
We observed a reduction in the concentration of kynure-
nine. In epidemiologic studies, increased kynurenine and 3-
hydroxykynurenine are associated with risk of acute coronary
events in the elderly (41). In addition, increased plasma
kynurenines predict the risk of acute myocardial infarction in
patients with suspected stable angina pectoris, in particular
among subjects with impaired glucose homeostasis (42).
Neopterin, a marker of interferon γ (IFN-γ ) activation, was
not altered. This result is in line with our previous finding that the
serum concentration of IFN-γ was not changed after replacing
SFAs with PUFAs (10). We observed a reduction in glycoprotein
acetyls, whereas expression levels of some proinflammatory
genes were increased in the Ex-diet group, which may indicate
a minor modulatory effect of n–6 PUFAs. The clinical relevance
of this needs to be further investigated.
We found that certain amino acids changed during the
intervention. First, cystathionine increased in the Ex-diet group.
Cystathionine is produced from homocysteine, and the first
enzyme in the trans-sulfuration pathway is cystathionine β-
synthase (CBS), which is a vitamin D receptor target gene (43).
Because bile acids have been shown to activate the vitamin D
receptor (44), we speculate that an increased concentration of
bile acids may induce the expression of CBS mRNA, mediating
the increase in cystathionine levels. Furthermore, the increases
in thiamine may be due to the higher fiber intake in the Ex-diet
group than in the C-diet group (10). The clinical importance of
these findings is at present unknown, but they may have potential
as objective biomarkers of dietary habits.
The mRNA level of LDLR was upregulated in the Ex-
diet group compared with the C-diet group. As PBMCs have
been suggested as a model system reflecting nutrition-related
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FIGURE 6 Graphical summary. Hypothetic physiologic changes that occur when replacing SFAs with PUFAs diet, as outlined in the Discussion.
Annotations: bold grey, no difference; plain grey (nonbold), not measured; bold blue, increased/higher; bold red, reduced/lower; italics: gene names. Possible
sequence of events: replacing SFAs with PUFAs changes the expression of LDLR, possibly via SREBP2 or other regulatory mechanisms. Higher expression of
LDLR causes a higher hepatic uptake of apoB-containing lipoproteins, which reduces plasma lipoprotein subclasses, both apoB- and apoAI-containing types.
This effect may be partially offset by higher expression of PCSK9. In PBMCs, controlled LXR activation may drive an increase in reverse cholesterol transport,
which includes synthesis of fatty acids for efflux or to esterify free cholesterol to cholesteryl esters; normally, this would also correspond to an inhibition
of β oxidation and modulation of inflammation-related gene expression. Higher hepatic cholesterol uptake both inhibits cholesterol synthesis, and activates
cholesterol efflux to the gut. Cholesterol-derived oxysterols activate LXR, which activates the bile salt production. Other bile constituents are also produced,
particularly from cysteine and other amino acids. Hepatic acetyl-CoA likely adjusts to a lower need for cholesterol synthesis, and directs energy surplus to
production of primary ketone bodies. In addition, lower SFA influx requires less immediate neutralization via the β oxidation pathway, which could be reflected
in lower hepatic oxidative stress. Abbreviations as in Figures 1–3.
gene expression reflects hepatic mRNA expression of LDLR.
It has been shown in animals that PUFAs upregulate the
LDLR protein and mRNA levels (46–48), and SFAs decrease
LDLR activity, and protein and mRNA abundance (46, 47),
and alter LDL composition and size (49). Interestingly, the
serum concentration of PCSK9 was increased, and PCSK9 is
regulated by SREBP similar to LDLR (50, 51). The depletion
of intracellular cholesterol concentrations, which leads to the
simultaneous upregulation of both LDLR and PCSK9 expression,
is a paradox observed by others (52, 53). The LXRA mRNA level
was upregulated in the Ex-diet group, and was the most important
variable explaining the variance in the multivariate analysis.
LXRα serves as a lipid sensor, and regulates the transcription
of genes involved in intracellular cholesterol homeostasis and
de novo lipogenesis (54). In the present study, both the mRNA
levels of SREBF1 and FASN were upregulated in the Ex-diet
group compared with the C-diet group. Normally an increase in
cholesterol influx would lead to downregulation of the LDLR
via SREBP2. However, the upregulation of the ABCG1 mRNA
level may potentially lead to an increased cholesterol efflux. In
mice it is well documented that LXRα activation induces 7α-
hydroxylase, the rate-limiting enzyme in the metabolic pathway
from cholesterol to bile acids in the liver (55). The increased
release of bile acids into the circulation is in accordance with
previous studies in which a diet rich in PUFAs has been
administered (56). The downregulation of UCP2 mRNA level
in the Ex-diet group may be due to downregulation of PPARD
mRNA level, since UCP2 and other β-oxidation enzymes,
including carnitine palmitoyltransferase, have been shown to be
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have previously shown that the plasma palmitic acid was reduced
in the Ex-diet group (10).
The strength of this study is the relatively high number of
subjects and the double-blind, randomized, and controlled study
design. The results of the multivariate analyses support and
strengthen our results from the univariate analyses. A limitation
of the study is that some of the observed effects may have been
caused by the increased intake of fiber and protein, and the
lower intake of carbohydrate in the Ex-diet group, and therefore
not exclusively by the replacement of SFAs with PUFAs.
Another limitation was that a small nonsignificant change in the
distribution of monocytes was seen between the groups; however,
as monocytes only constitute a small fraction of the PBMCs, the
clinical relevance remains to be elucidated.
In conclusion, applying metabolic profiling in a randomized
controlled dietary intervention trial holds the potential to extend
our understanding of the effects of dietary fat on CVD risk.
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